The Pivotal Role of the Membrane-Bound O-Acyltransferase Domain Containing 7 in Non-Alcoholic Fatty Liver Disease

Round 1

Reviewer 1 Report

The review that the authors are presenting is thorough, well-balanced, and does not appear to require any other factual inclusions. Indeed, it provides the field with a very useful review of the current knowledge of MBOAT7 and its involvement in NAFLD.

Author Response

Dear Reviewer 1,

see our comments to your review report in the attached pdf-file.

Regards

Ralf Weiskirchen

Author Response File: Author Response.pdf

Reviewer 2 Report

Title: The Pivotal Role of MBOAT7 in Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty Liver Disease (NAFLD) is a multifaceted condition with a diverse spectrum of disorders, ranging from hepatic steatosis to cirrhosis and hepatocellular carcinoma. The MBOAT7 (lysophosphatidylinositol acyltransferase 1) is well reported in the acyl-transfer of polyunsaturated fatty acids (PUFAs) to lysophosphatidylinositol. This review highlights the involvement of MBOAT7 and its associated single nucleotide polymorphism in the liver pathophysiology of NASH. The regulation of phospholipid and arachidonic acid metabolism to reduce the cellular triglyceride by MBOAT7 is well explained in the overview. The manuscript is well written. However, there are a few additional minor comments for improving the view of this manuscript as follows.

1. The information provided in this review is repeated in various parts of this manuscript. Hence, the author must remove such verbose to reduce the word count.
2. The information under “4.1. Non Canonical and Canonical Pathway” and “4.2. In Vitro and In Vivo Studies on MBOAT7 Correlation to NAFLD” shares closely related information and reference. It is recommended to merge both topics and combine the information to have a perfect correlation rather than segregating the information based on in vivo, in vitro, or Canonical Pathways.
3. Under the subheading “Challenges and Recent Progress in Treating Complex NAFLD” the author has limited information for MBOAT7 but has other information for the other molecular targets. The author is expected to discuss and focus more on MBOAT7 as a possible therapeutic option than describing other molecular targets.

Author Response

Dear Reviewer 2,

see our comments to your review report in the attached pdf-file.

Regards

Ralf Weiskirchen

Author Response File: Author Response.pdf

Reviewer 3 Report

This review focuses on a condition that is quite prevalent in the population, more so in men than in women. The information is relevant and of recent date. The article is of interest to both researchers and the general public.

However the authors have small gaps (missing letters), and it is necessary to read the text again to correct them:

For example, lines 50-51, 311

The text is fluent, the conclusions are pertinent and correlated with the researched information.

Misspelled letters, which can be corrected quite effectively.

Author Response

Dear Reviewer 3,

see our comments to your review report in the attached pdf-file.

Regards

Ralf Weiskirchen

Author Response File: Author Response.pdf